HRP20080546T3 - Combination of an antagonist of the tp-receptors and clopidogrel - Google Patents

Combination of an antagonist of the tp-receptors and clopidogrel

Info

Publication number
HRP20080546T3
HRP20080546T3 HR20080546T HRP20080546T HRP20080546T3 HR P20080546 T3 HRP20080546 T3 HR P20080546T3 HR 20080546 T HR20080546 T HR 20080546T HR P20080546 T HRP20080546 T HR P20080546T HR P20080546 T3 HRP20080546 T3 HR P20080546T3
Authority
HR
Croatia
Prior art keywords
clopidogrel
combination
antagonist
receptors
pharmaceutically acceptable
Prior art date
Application number
HR20080546T
Other languages
English (en)
Croatian (hr)
Inventor
Cloarec-Blanchard Laure
Corda Stefano
Lerond Laurence
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20080546T3 publication Critical patent/HRP20080546T3/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20080546T 2003-10-03 2008-12-03 Combination of an antagonist of the tp-receptors and clopidogrel HRP20080546T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311595A FR2860436B1 (fr) 2003-10-03 2003-10-03 Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
PCT/FR2004/002489 WO2005032533A1 (fr) 2003-10-03 2004-10-01 Nouvelle association d'un anti-atherothrombotique et d’un antiagregant plaquettaire

Publications (1)

Publication Number Publication Date
HRP20080546T3 true HRP20080546T3 (en) 2009-01-31

Family

ID=34307392

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080546T HRP20080546T3 (en) 2003-10-03 2008-12-03 Combination of an antagonist of the tp-receptors and clopidogrel

Country Status (29)

Country Link
US (2) US20070054934A1 (de)
EP (1) EP1677779B1 (de)
JP (1) JP2007507475A (de)
KR (1) KR100782246B1 (de)
CN (1) CN100453075C (de)
AR (1) AR046043A1 (de)
AT (1) ATE409033T1 (de)
AU (1) AU2004277734B2 (de)
BR (1) BRPI0415043A (de)
CA (1) CA2540062A1 (de)
CY (1) CY1108388T1 (de)
DE (1) DE602004016762D1 (de)
DK (1) DK1677779T3 (de)
EA (1) EA009418B1 (de)
ES (1) ES2314457T3 (de)
FR (1) FR2860436B1 (de)
GE (1) GEP20084546B (de)
HK (1) HK1093900A1 (de)
HR (1) HRP20080546T3 (de)
MA (1) MA28081A1 (de)
MX (1) MXPA06003713A (de)
MY (1) MY137953A (de)
NO (1) NO20061944L (de)
NZ (1) NZ545988A (de)
PL (1) PL1677779T3 (de)
PT (1) PT1677779E (de)
SI (1) SI1677779T1 (de)
UA (1) UA80220C2 (de)
WO (1) WO2005032533A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05014086A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico.
FR2899473B1 (fr) * 2006-04-07 2008-06-13 Servier Lab Utilisation d'un compose anti-atherothrombotique pour l'obtention de medicaments destines au traitement des troubles vasculaires
NZ580162A (en) 2007-04-13 2012-10-26 Millennium Pharm Inc Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination

Also Published As

Publication number Publication date
ATE409033T1 (de) 2008-10-15
KR100782246B1 (ko) 2007-12-05
JP2007507475A (ja) 2007-03-29
FR2860436B1 (fr) 2006-01-20
GEP20084546B (en) 2008-11-25
MA28081A1 (fr) 2006-08-01
UA80220C2 (en) 2007-08-27
CY1108388T1 (el) 2014-02-12
US20100056564A1 (en) 2010-03-04
EA200600657A1 (ru) 2006-08-25
EP1677779A1 (de) 2006-07-12
EA009418B1 (ru) 2007-12-28
CN100453075C (zh) 2009-01-21
KR20060061399A (ko) 2006-06-07
NO20061944L (no) 2006-05-02
CN1859902A (zh) 2006-11-08
AU2004277734B2 (en) 2007-05-24
PT1677779E (pt) 2008-10-23
US20070054934A1 (en) 2007-03-08
DE602004016762D1 (de) 2008-11-06
EP1677779B1 (de) 2008-09-24
FR2860436A1 (fr) 2005-04-08
MY137953A (en) 2009-04-30
MXPA06003713A (es) 2006-06-14
HK1093900A1 (en) 2007-03-16
PL1677779T3 (pl) 2009-02-27
AR046043A1 (es) 2005-11-23
SI1677779T1 (sl) 2009-02-28
CA2540062A1 (fr) 2005-04-14
AU2004277734A1 (en) 2005-04-14
DK1677779T3 (da) 2009-01-05
AU2004277734B8 (en) 2005-04-14
NZ545988A (en) 2008-11-28
BRPI0415043A (pt) 2006-12-12
WO2005032533A1 (fr) 2005-04-14
ES2314457T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ME01992B (me) Jedinjenje diarilhidantoina
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
MY140572A (en) Quinazolinone derivatives as parp inhibitors
SE0202463D0 (sv) Novel compounds
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
CL2004000382A1 (es) Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6.
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
EP1248612A4 (de) Neue substanzen und verbindungen als protease-inhibitoren
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
CR9587A (es) Derivados de piridazina
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
RS52979B (en) INHIBITORI P38 MAP KINAZE
ATE406360T1 (de) Antagonisten der opioidrezeptoren
RS50807B (sr) 3,11 b-cis-dihidrotetrabenazin za lečenje šizofrenije i drugih psihoza
NO20025590D0 (no) Fenylglycin-derivater
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
HRP20080027T3 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
NO20033288D0 (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
HRP20090017T3 (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
RS52679B (en) RENIN INHIBITORS
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide